H.C. Wainwright analyst Joseph Pantginis downgraded VYNE Therapeutics (VYNE) to Neutral from Buy.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VYNE:
- Why Is VYNE Therapeutics Stock (VYNE) Down 70% Today?
- VYNE Therapeutics Ends Phase 2b Trial for Repibresib
- VYNE says Phase 2B trial with repibresib gel did not meet primary endpoint
- Promising Developments in VYNE Therapeutics’ Repibresib Gel for Nonsegmental Vitiligo Drive Buy Rating
- Promising Potential of VYNE Therapeutics’ Repibresib Gel in Phase IIb Study